Vitamin D and multiple sclerosis.

  • Asghar Amini Harandi Mail Department of Biochemistry, School of Medicine, Jahrom University of Medical Sciences, Jahrom, Iran.
  • Ali Amini Harandi Department of Neurology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Hossein Pakdaman Department of Neurology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Mohammad Ali Sahraian MS Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
Multiple Sclerosis, Polymorphism, Vitamin D, Vitamin D Receptor


Multiple sclerosis (MS) is a chronic demyelinating disease and also is one of the most common disabling neurological disorders in young and middle-aged adults. The main pathogenesis of MS has long been thought to be an immune mediated disorder of the central nervous system. The function of the immune system is under the influence of vitamin D which as a modulator of immune response could play a role in autoimmune diseases including MS. Deficiency of vitamin D or variations in DNA sequence (polymorphism) of vitamin D receptor gene diminishes its optimal function on immune system that consequently could lead to increasing risk of MS. However, its role in development and modulating the course of MS is still under investigation. In this review we aimed to discuss the role of vitamin D in body, immune system and consequently altering the risk of MS.


1. Kidd PM. Multiple sclerosis, an autoimmune inflammatory disease: prospects for its integrative management. Altern Med Rev 2001; 6(6): 540-66.
2. Ziemann U, Wahl M, Hattingen E, Tumani H. Development of biomarkers for multiple sclerosis as a neurodegenerative disorder. Prog Neurobiol 2011; 95(4): 670-85.
3. Sahraian MA, Pakdaman H, Harandi AA. Is it time to revise the classification of geographical distribution of multiple sclerosis? Iran J Neurol 2012; 11(2): 77-8.
4. Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995; 16(1): 34-8.
5. Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol 2008; 7(3): 268-77.
6. Oksenberg JR, Baranzini SE, Sawcer S, Hauser SL. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet 2008; 9(7): 516-26.
7. Ebers GC, Kukay K, Bulman DE, Sadovnick AD, Rice G, Anderson C, et al. A full genome search in multiple sclerosis. Nat Genet 1996; 13(4): 472-6.
8. Fukazawa T, Yabe I, Kikuchi S, Sasaki H, Hamada T, Miyasaka K, et al. Association of vitamin D receptor gene polymorphism with multiple sclerosis in Japanese. J Neurol Sci 1999; 166(1): 47-52.
9. Huang J, Xie ZF. Polymorphisms in the vitamin D receptor gene and multiple sclerosis risk: a meta-analysis of case- control studies. J Neurol Sci 2012; 313(1-2): 79-85.
10. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004; 80(6 Suppl): 1678S-88S.
11. Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 2004; 79(3): 362-71.
12. Moreiraa TS, Hamadehb MJ. The role of vitamin D deficiency in the pathogenesis of type 2 diabetes mellitus. e-SPEN, the European e-Journal of Clinical Nutrition and Metabolism 2010; 5(4): e155-e65.
13. Lips P. Vitamin D physiology. Prog Biophys Mol Biol 2006; 92(1): 4-8.
14. Bhalla AK, Amento EP, Serog B, Glimcher LH. 1,25-Dihydroxyvitamin D3 inhibits antigen-induced T cell activation. J Immunol 1984; 133(4): 1748-54.
15. Griffin MD, Xing N, Kumar R. Vitamin D and its analogs as regulators of immune activation and antigen presentation. Annu Rev Nutr 2003; 23: 117-45.
16. Martineau AR, Wilkinson KA, Newton SM, Floto RA, Norman AW, Skolimowska K, et al. IFN-gamma- and TNF-independent vitamin D-inducible human suppression of mycobacteria: the role of cathelicidin LL- 37. J Immunol 2007; 178(11): 7190-8.
17. Almerighi C, Sinistro A, Cavazza A, Ciaprini C, Rocchi G, Bergamini A. 1Alpha,25-dihydroxyvitamin D3 inhibits CD40L-induced pro-inflammatory and immunomodulatory activity in human monocytes. Cytokine 2009; 45(3): 190-7.
18. Xu H, Soruri A, Gieseler RK, Peters JH. 1,25-Dihydroxyvitamin D3 exerts opposing effects to IL-4 on MHC class-II antigen expression, accessory activity, and phagocytosis of human monocytes. Scand J Immunol 1993; 38(6): 535-40.
19. Chen S, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE. Modulatory effects of 1,25- dihydroxyvitamin D3 on human B cell differentiation. J Immunol 2007; 179(3): 1634-47.
20. Cantorna MT, Hayes CE, DeLuca HF. 1,25- Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A 1996; 93(15): 7861-4.
21. Cantorna MT, Hayes CE, DeLuca HF. 1,25- Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr 1998; 128(1): 68-72.
22. Cantorna MT, Munsick C, Bemiss C, Mahon BD. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 2000; 130(11): 2648-52.
23. Zella JB, DeLuca HF. Vitamin D and autoimmune diabetes. J Cell Biochem 2003; 88(2): 216-22.
24. Correale J, Ysrraelit MC, Gaitan MI. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain 2009; 132(Pt 5): 1146-60.
25. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005; 26(5): 662-87.
26. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 2004; 79(5): 820-5.
27. Soni M, Kos K, Lang IA, Jones K, Melzer D, Llewellyn DJ. Vitamin D and cognitive function. Scand J Clin Lab Invest Suppl 2012; 243: 79-82.
28. Smolders J, Damoiseaux J, Menheere P, Hupperts R. Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol 2008; 194(1-2): 7-17.
29. Doria A, Arienti S, Rampudda M, Canova M, Tonon M, Sarzi-Puttini P. Preventive strategies in systemic lupus erythematosus. Autoimmun Rev 2008; 7(3): 192-7.
30. Cutolo M, Otsa K, Uprus M, Paolino S, Seriolo B. Vitamin D in rheumatoid arthritis. Autoimmun Rev 2007; 7(1): 59-64.
31. Kamen DL, Cooper GS, Bouali H, Shaftman SR, Hollis BW, Gilkeson GS. Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev 2006; 5(2): 114-7.
32. Ruiz-Irastorza G, Egurbide MV, Olivares N, Martinez-Berriotxoa A, Aguirre C. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology (Oxford) 2008; 47(6): 920-3.
33. Pelajo CF, Lopez-Benitez JM, Miller LC. Vitamin D and autoimmune rheumatologic disorders. Autoimmun Rev 2010; 9(7): 507-10.
34. Bouillon R, Verstuyf A, Branisteanu D, Waer M, Mathieu C. Immune modulation by vitamin D analogs in the prevention of autoimmune diseases. Verh K Acad Geneeskd Belg 1995; 57(5): 371-85. [In Dutch].
35. DeLuca HF, Cantorna MT. Vitamin D: its role and uses in immunology. FASEB J 2001; 15(14): 2579-85.
36. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001; 358(9292): 1500-3.
37. Merlino LA, Curtis J, Mikuls TR, Cerhan JR, Criswell LA, Saag KG. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum 2004; 50(1): 72-7.
38. Pierrot-Deseilligny C. Clinical implications of a possible role of vitamin D in multiple sclerosis. J Neurol 2009; 256(9): 1468-79.
39. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006; 296(23): 2832-8.
40. Kragt J, van Amerongen B, Killestein J, Dijkstra C, Uitdehaag B, Polman C, et al. Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. Mult Scler 2009; 15(1): 9-15.
41. Smolders J, Menheere P, Kessels A, Damoiseaux J, Hupperts R. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 2008; 14(9): 1220-4.
42. Marshall TG. Vitamin D discovery outpaces FDA decision making. Bioessays 2008; 30(2): 173-82.
43. Haussler MR. Vitamin D receptors: nature and function. Annu Rev Nutr 1986; 6: 527-62.
44. Henry HL, Norman AW. Vitamin D: metabolism and biological actions. Annu Rev Nutr 1984; 4: 493-520.
45. Tagami T, Lutz WH, Kumar R, Jameson JL. The interaction of the vitamin D receptor with nuclear receptor corepressors and coactivators. Biochem Biophys Res Commun 1998; 253(2): 358-63.
46. Yasmin R, Williams RM, Xu M, Noy N. Nuclear import of the retinoid X receptor, the vitamin D receptor, and their mutual heterodimer. J Biol Chem 2005; 280(48): 40152-60.
47. Rigby WF, Denome S, Fanger MW. Regulation of lymphokine production and human T lymphocyte activation by 1,25- dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA. J Clin Invest 1987; 79(6): 1659-64.
48. Trembleau S, Germann T, Gately MK, Adorini L. The role of IL-12 in the induction of organ-specific autoimmune diseases. Immunol Today 1995; 16(8): 383-6.
49. Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, O'Garra A. 1alpha,25- Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 2001; 167(9): 4974-80.
50. Gregori S, Giarratana N, Smiroldo S, Uskokovic M, Adorini L. A 1alpha,25- dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 2002; 51(5): 1367-74.
51. Adorini L, Penna G. Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol 2008; 4(8): 404-12.
52. Mathieu C, Adorini L. The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med 2002; 8(4): 174-9.
53. Valdivielso JM, Fernandez E. Vitamin D receptor polymorphisms and diseases. Clin Chim Acta 2006; 371(1-2): 1-12.
54. Tanaka A, Nezu S, Uegaki S, Kikuchi K, Shibuya A, Miyakawa H, et al. Vitamin D receptor polymorphisms are associated with increased susceptibility to primary biliary cirrhosis in Japanese and Italian populations. J Hepatol 2009; 50(6): 1202-9.
55. Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. Gene 2004; 338(2): 143-56.
56. Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 1998; 13(3): 325-49.
57. Smolders J, Peelen E, Thewissen M, Menheere P, Tervaert JW, Hupperts R, et al. The relevance of vitamin D receptor gene polymorphisms for vitamin D research in multiple sclerosis. Autoimmun Rev 2009; 8(7): 621-6.
58. Harada K, Nakanuma Y. Biliary innate immunity and cholangiopathy. Hepatol Res 2007; 37(Suppl 3): S430-S437.
59. Scharla SH. Prevalence of subclinical vitamin D deficiency in different European countries. Osteoporos Int 1998; 8(Suppl 2): S7-12.
60. Grootjans-Geerts I. [Hypovitaminosis D: a veiled diagnosis]. Ned Tijdschr Geneeskd 2001; 145(43): 2057-60.
61. Gannage-Yared MH, Chemali R, Yaacoub N, Halaby G. Hypovitaminosis D in a sunny country: relation to lifestyle and bone markers. J Bone Miner Res 2000; 15(9): 1856-62.
62. Harandi AA, Shahbeigi S, Pakdaman H, Fereshtehnejad SM, Nikravesh E, Jalilzadeh R. Association of serum 25(OH) vitamin D3 concentration with severity of multiple sclerosis. Iran J Neurol 2012; 11(2): 54-8.
63. Gloth FM, III, Tobin JD. Vitamin D deficiency in older people. J Am Geriatr Soc 1995; 43(7): 822-8.
64. Holick MF. McCollum Award Lecture, 1994: vitamin D--new horizons for the 21st century. Am J Clin Nutr 1994; 60(4): 619-30.
65. Kampman MT, Wilsgaard T, Mellgren SI. Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle. J Neurol 2007; 254(4): 471-7.
66. Islam T, Gauderman WJ, Cozen W, Mack TM. Childhood sun exposure influences risk of multiple sclerosis in monozygotic twins. Neurology 2007; 69(4): 381-8.
67. Goldacre MJ, Seagroatt V, Yeates D, Acheson ED. Skin cancer in people with multiple sclerosis: a record linkage study. J Epidemiol Community Health 2004; 58(2): 142-4.
68. van der Mei IA, Ponsonby AL, Dwyer T, Blizzard L, Simmons R, Taylor BV, et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ 2003; 327(7410): 316.
69. Rahnavard Z, Eybpoosh S, Homami MR, Meybodi HA, Azemati B, Heshmat R, et al. Vitamin d deficiency in healthy male population: results of the Iranian multi- center osteoporosis study. Iran J Public Health 2010; 39(3): 45-52.
70. Allison RS. Geographic distribution of multiple sclerosis. Preliminary notes on a comparative study of prevalence in Charleston, S.C. and Halifax, N.S. Acta Psychiatr Scand Suppl 1960; 35(147): 18-22.
71. Alter M, Kahana E, Loewenson R. Migration and risk of multiple sclerosis. Neurology 1978; 28(11): 1089-93.
72. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 2007; 61(4): 288-99.
73. Sadovnick AD, Duquette P, Herrera B, Yee IM, Ebers GC. A timing-of-birth effect on multiple sclerosis clinical phenotype. Neurology 2007; 69(1): 60-2.
74. Templer DI, Trent NH, Spencer DA, Trent A, Corgiat MD, Mortensen PB, et al. Season of birth in multiple sclerosis. Acta Neurol Scand 1992; 85(2): 107-9.
75. Willer CJ, Dyment DA, Sadovnick AD, Rothwell PM, Murray TJ, Ebers GC. Timing of birth and risk of multiple sclerosis: population based study. BMJ 2005; 330(7483): 120.
76. Munger KL, Zhang SM, O'Reilly E, Hernan MA, Olek MJ, Willett WC, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004; 62(1): 60-5.
77. Cantorna MT. Vitamin D and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence? Proc Soc Exp Biol Med 2000; 223(3): 230-3.
78. Cantorna MT. Vitamin D and its role in immunology: multiple sclerosis, and inflammatory bowel disease. Prog Biophys Mol Biol 2006; 92(1): 60 -4.
How to Cite
Harandi AA, Harandi AA, Pakdaman H, Sahraian MA. Vitamin D and multiple sclerosis. Curr J Neurol. 13(1):1-6.
Special Articles